Vertex Inc. (VERX)
Cramer's Stop Trading: Vertex Pharmaceuticals
CNBC's Jim Cramer explains why he is keeping an eye on shares of Vertex Pharmaceuticals.
Vertex Non-Opioid Drug Doesn't Best Placebo In Back Pain Study. The Stock Is Plunging.
Vertex Pharmaceuticals reported that its non-opioid drug reduced back pain significantly. But Vertex stock plunged as a placebo showed similar results.
Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy
I'm updating my recent “Buy” thesis on Vertex Pharmaceuticals Incorporated — spoiler alert, I am as bullish, if not more so, than I was back in September, despite a recent sell-off. Vertex's CF franchise remains robust, with TRIKAFTA generating $2.77bn in Q3 revenues and the upcoming Vanzacaftor triple therapy expected to drive further growth. Casgevy, a CRISPR-based therapy for Sickle Cell Disease and TDT, shows promising commercial potential, with multi-billion-dollar peak revenue projections and expanding global approvals.
Vertex Has $5 Billion-Plus Opportunity In Pain And Kidney Disease Programs, Analyst Upgrades Stock
Jefferies has upgraded Vertex Pharmaceuticals Inc. VRTX, citing the company's robust cystic fibrosis base business and the additional upside from the new LNP/ mRNA therapy (around $1 billion opportunity) and “triple pill” regimens.
Vertex (VERX) is an Incredible Growth Stock: 3 Reasons Why
Vertex (VERX) could produce exceptional returns because of its solid growth attributes.
Vertex (VERX) is a Great Momentum Stock: Should You Buy?
Does Vertex (VERX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Vertex, Inc. (VERX) Hit a 52 Week High, Can the Run Continue?
Vertex (VERX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Is Vertex Stock Worth Buying Despite Its 105% Year-to-Date Rally?
VERX's impressive financial performance, accelerating cloud transition and strategic positioning make it a strong contender in the tax compliance market.
Vertex Pharma: Why I Am Buying This Dip
Vertex Pharmaceuticals reported strong Q3 earnings, yet the stock has pulled back, presenting a buying opportunity. The company's robust pipeline, particularly Suzetrigine for acute pain and CASGEVY gene therapy, positions Vertex for significant growth. Vertex's financial health, with no traditional debt and substantial cash reserves, supports its aggressive push into new therapeutic areas and product launches.
Vertex Pharmaceuticals initiated with a Buy at Citi
Citi initiated coverage of Vertex Pharmaceuticals with a Buy rating and $575 price target. The firm believes Vertex is positioned to remain a leader in the cystic fibrosis, or CF, space, with its current product portfolio of Trikafta, Kalydeco, Orkambi, Symdeko and the anticipated approval of the vanza triple which has a PDUFA goal date of January 2, 2025. The firm sees the vanza triple product taking a "notable portion" of the CF market with $8B sales in 2030, the analyst tells investors.
Why Vertex (VERX) Might be Well Poised for a Surge
Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
3 Reasons Growth Investors Will Love Vertex (VERX)
Vertex (VERX) possesses solid growth attributes, which could help it handily outperform the market.
